Bone Therapeutics announces final results from Phase I/IIA ALLOB study

Bone Therapeutics announces positive final results in the Phase I/IIA delayed-union study of its allogeneic bone cell therapy product ALLOB in 21 patients, supporting the future clinical development of the delayed union indication. The Company also announces the development of an optimized production process for ALLOB, which the Company believes delivers critical improvements in consistency, scalability, cost-effectiveness and ease of use. Discover the official press release here.

Read more

Caprion Biosciences acquires US-Based Primity Bio

Caprion Biosciences Expands its Biomarker and Immune Monitoring Franchise by Acquiring US-Based Primity Bio. Read the official press release here.

Read more